Momelotinib
- Generic Name
- Momelotinib
- Brand Names
- Ojjaara, Omjjara
- Drug Type
- Small Molecule
- Chemical Formula
- C23H22N6O2
- CAS Number
- 1056634-68-4
- Unique Ingredient Identifier
- 6O01GMS00P
- Background
Momelotinib is a Janus Kinase 1 (JAK1) and 2 (JAK2) inhibitor. It is a competitive inhibitor of JAK ATP binding. First approved by the FDA on September 15, 2023, momelotinib is used to treat myelofibrosis. Myelofibrosis (MF) is a group of myeloproliferative neoplasms characterized by abnormal proliferative hematopoietic stem cells, leading to the release of ...
- Indication
Momelotinib is indicated for the treatment of intermediate or high-risk myelofibrosis (MF), including primary MF or secondary MF [postpolycythemia vera (PV) and post-essential thrombocythemia (ET)], in adults with anemia.
- Associated Conditions
- High risk Myelofibrosis, Intermediate risk Myelofibrosis
- Associated Therapies
- -
Health Canada approves GSK's Ojjaara for myelofibrosis in anaemia patients
Health Canada approves GSK’s Ojjaara for treating myelofibrosis in adults with moderate-to-severe anaemia, based on Phase III MOMENTUM trial results.
Ojjaara medication: Price, side effects, vs. Jakafi, and more
Ojjaara treats myelofibrosis (MF) by inhibiting JAK proteins, reducing abnormal blood cell production, and promoting healthy blood cell formation. It also blocks ACVR1 to stimulate red blood cell production, alleviating symptoms and reducing spleen size and blood transfusion needs.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath